Journal
INTERFACE FOCUS
Volume 9, Issue 2, Pages -Publisher
ROYAL SOC
DOI: 10.1098/rsfs.2018.0077
Keywords
prostate cancer; diagnostics; biomarkers; lectins; glycans; prostate-specific antigen
Categories
Funding
- Slovak Scientific Grant Agency VEGA [2/0137/18, 2/0090/16]
- Slovak Research and Development Agency [APVV 17-0300]
- ERC Proof of Concept grant [825586]
- Innovative Training Network [813120]
- ERDF [26240120007]
- European Research Council (ERC) [825586] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
The initial part of this review details the controversy behind the use of a serological level of prostate-specific antigen (PSA) for the diagnostics of prostate cancer (PCa). Novel biomarkers are in demand for PCa diagnostics, outperforming traditional PSA tests. The review provides a detailed and comprehensive summary that PSA glycoprofiling can effectively solve this problem, thereby considerably reducing the number of unnecessary biopsies. In addition, PSA glycoprofiling can serve as a prognostic PCa biomarker to identify PCa patients with an aggressive form of PCa, avoiding unnecessary further treatments which are significantly life altering (incontinence or impotence).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available